Health News

ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1

Author: Australian Business

DENVER, Sept. 12, 2013 /PRNewswire/ -- ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time, compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a......

More...

More Articles...

Clutter Cleanup Methods Revealed by Address Our Mess
Northside Medical Center Nurses Give Notice for One-Day Strike
Misonix Supports Uganda Spine Surgery Mission with Ultrasonic BoneScalpel™
Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T
Boston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System
Actavis Launches Generic Version of Opana® ER
Alvi Armani Hair Loss Research Discontinues 'Hair Cloning' Research. Hair Replication Not a Feasible Technology. To Focus on Patented Origenere TR1 Natural Plant Extract for Hair Growth.
Illinois Lottery Kicks Off New 'Carolyn Adams Ticket for the Cure' Instant Game
FeverAll® Acetaminophen Suppositories Offer A Great Choice For Hispanic Moms Of Small Children

Page 1762 of 1908